References
- 1. Bittner V. Menopause, age, and cardiovascular risk: a complex relationship. J Am Coll Cardiol. 2009; 54(25):2374–5.10.1016/j.jacc.2009.10.00820082926
- 2. Magnani JW, Moser CB, Murabito JM, et al. Age of natural menopause and atrial fibrillation: the Framingham Heart Study. Am Heart J. 2012; 163(4):729–34. 3 Vaidya D, Becker DM,10.1016/j.ahj.2012.01.010333486122520541
- 3. Bittner V, Mathias RA, Ouyang P. Ageing, menopause, and ischaemic heart disease mortality in England, Wales, and the United States: modelling study of national mortality data. BMJ. 2011; 343:d5170.10.1136/bmj.d5170316716421896608
- 4. Malkin CJ, Pugh PJ, Jones RD, Jones TH, Channer KS. Testosterone as a protective factor against atherosclerosis--immunomodulation and influence upon plaque development and stability. J Endocrinol. 2003; 178(3):373–80.10.1677/joe.0.178037312967330
- 5. Phillips GB. Is atherosclerotic cardiovascular disease an endocrinological disorder? The estrogen-androgen paradox. J Clin Endocrin Metab. 2005; 90(5):2708-2711.10.1210/jc.2004-201115687329
- 6. Burke A.P., Farb A., Malcom G., Virmani R.. Effect of menopause on plaque morphologic characteristics in coronary atherosclerosis, Am Heart J, 2001; vol. 141 2:58-62.10.1067/mhj.2001.10994611174360
- 7. Rossouw JE, Prentice PL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007; 297(13):1465-1477.10.1001/jama.297.13.146517405972
- 8. Peter I, Kelley-Hedgepeth A, Huggins GS, et al. Association between arterial stiffness and variations in oestrogen-related genes. J Hum Hypertens. 2009; 23(10):636-644.10.1038/jhh.2009.1274626019194457
- 9. Debing E, Peeters E, Duquet W, Poppe K, Velkeniers B, Van den Brande P. Endogenous sex hormone levels in postmenopausal women undergoing carotid artery endarter-ectomy. Eur J Endocrinol. 2007; 156(6):687-69310.1530/EJE-06-070217535869
- 10. Austin C.E.. Chronic and acute effects of oestrogens on vascular contractility, J Hypertens, 2000, vol. 18:1365-1378.10.1097/00004872-200018100-0000311057423
- 11. HigashiY., Sanada M., Sasaki S., et al. Effect of estrogen replacement therapy on endothelial function in peripheral resistance arteries in normotensive and hypertensive postmenopausal women, Hypertension, 2001; vol. 37:651-657.10.1161/01.HYP.37.2.651
- 12. Bechlioulis A, Naka KK, Calis KA, et al. Cardiovascular Effects of Endogenous Estrogen and Hormone Therapy. Curr Vasc Pharmacol. 2010; 8:249-258.10.2174/15701611079088697419485910
- 13. Badimon, L. New challenges in the etiopathogenesis of atherothrombosis. Cerebrovasc Dis 11 Suppl 1. 2001;80-84.10.1159/00004912911244204
- 14 Hodges Y.K., Tung L., Yan X.D., Graham J.D., Horwitz K.B., Horwitz L.D..Estrogen receptors alpha and beta: prevalence of estrogen receptor beta mRNA in human vascular smooth muscle and transcriptional effects. Circulation, 2000; vol.101:1792-1798.10.1161/01.CIR.101.15.179210769279
- 15. Shearman AM, Cooper JA, Kotwinski PJ, et al. Estrogen receptor alpha gene variation is associated with risk of myocardial infarction in more than seven thousand men from five cohorts. Circ Res. 2006; 98(5):590-592.10.1161/01.RES.0000210578.62102.a616484614
- 16. Hodges YK, Tung L, Yan XD, Graham JD, Horwitz KB, Horwitz LD. Estrogen receptors alpha and beta: prevalence of estrogen receptor beta mRNA in human vascular smooth muscle and transcriptional effects. Circulation. 2000; 101(15):1792-1798.10.1161/01.CIR.101.15.1792
- 17. Schuit SC, Oei HH, Witteman JC, et al. Estrogen receptor alpha gene polymorphisms and risk of myocardial infarction. JAMA. 2004; 291(24):2969-2977.10.1001/jama.291.24.296915213208
- 18. Schuit SC, de Jong FH, Stolk L, et al. Estrogen receptor alpha gene polymorphisms are associated with estradiol levels in postmenopausal women. Eur J Endocrinol. 2005; 153(2):327-334.10.1530/eje.1.0197316061840
- 19. Malkin CJ, Pugh PJ, Jones RD, Jones TH, Channer KS. Testosterone as a protective factor against atherosclerosis--immunomodulation and influence upon plaque development and stability. J Endocrinol. 2003; 178(3):373–80.10.1677/joe.0.178037312967330
- 20. Liu PY, Death AK, Handelsman DJ. Androgens and cardio-vascular disease. Endocr Rev. 2003; 24(3):313-340.10.1210/er.2003-000512788802
- 21. Yeap BB, Hyde Z, Almeida OP, et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab. 2009; 94(7):2353-2359.10.1210/jc.2008-2416
- 22. Gonzalez-Clemente JM, Gimenez-Palop O, Vilardell C, Caixas A, Gimenez-Perez G. Are statins analogues of vitamin D? Lancet. 2006; 368(9543):1233.10.1016/S0140-6736(06)69507-X
- 23. Perez-Castrillon JL, Vega G, Abad L, et al. Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol. 2007; 99(7):903-905.10.1016/j.amjcard.2006.11.03617398180
- 24. Michos ED, Melamed ML. Vitamin D and cardiovascular disease risk. Curr Opin Clin Nutr Metab Care. 2008; 11(1):7-12.10.1097/MCO.0b013e3282f2f4dd18090651
- 25. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men:a prospective study. Arch Intern Med. 2008; 168(11):1174-1180.10.1001/archinte.168.11.1174371939118541825
- 26. Pilz S, Dobnig H, Nijpels G, et al. Vitamin D and mortality in older men and women. Clin Endocrinol (Oxf). 2009; 71(5):666-672.10.1111/j.1365-2265.2009.03548.x19226272
- 27. Wannamethee SG, Tchernova J, Whincup P, et al. Plasma leptin: associations with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease. Atherosclerosis. 2007; 191(2):418-426.10.1016/j.atherosclerosis.2006.04.01216712853
- 28. Wolk R, Berger P, Lennon RJ, Brilakis ES, Johnson BD, Somers VK. Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol. 2004; 44(9):1819-1824.10.1016/j.jacc.2004.07.05015519013
- 29. Kizer J, Barzilay JI, Kuller LH, Gottdiener JS. Adiponectin and risk of coronary heart disease in older men and women. J Clin Endocrin Metab. 2008; 93(9):3357-3364.10.1210/jc.2008-0640256785318593765
- 30. Butler J, Kalogeropoulos A, Georgiopoulou V, et al, for the Health ABC Study. Serum resistin concentrations and risk of new onset heart failure in older persons: the health, aging, and body composition (Health ABC) study. Arterioscler Thromb Vasc Biol. 2009; 29(7):1144-1149.10.1161/ATVBAHA.109.186783275729019372460
- 31. Frankel DS, Vasan RS, D’Agostino RB Sr, et al. Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol. 2009; 53(9):754-762.10.1016/j.jacc.2008.07.073267679319245965
- 32. Bonaa K, Njolstad I, Ueland P. NORVIT trial investigators. Homocysteine lowering and cadiovascular evens after acute myocardial infarction. N Engl J Med. 2006; 354(15):1578-1588.10.1056/NEJMoa05522716531614
- 33. Shi RZ, Wang JC, Huang SH, Wang XJ, Li QP. Angiotensin II induces vascular endothelial growth factor synthesis in mesenchymal stem cells. Exp Cell Res. 2009; 315(1):10-15.10.1016/j.yexcr.2008.09.02418973754
- 34. Shan H, Bai X, Chen X. Angiotensin II induces endothelial cell senescence via the activation of mitogen-activated protein-kinases. Cell Biochem Funct. 2008; 26(4):459-466.10.1002/cbf.146718383564
- 35. Javeshghani D, Sairam MR, Neves MF, Schiffrin EL, Touyz RM. Angiotensin II induces vascular dysfunction without exacerbating blood pressure elevation in a mouse model of menopause-associated hypertension. J Hypertens. 2006; 24(7):1365-1373.10.1097/01.hjh.0000234117.25401.f816794486
- 36. Vinh A, Widdop RE, Drummond GR, Gaspari TA. Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. Cardiovasc Res. 2008; 77(1):178-187.10.1093/cvr/cvm02118006471
- 37. Sluimer JC, Gasc JM, Hamming I, et al. Angiotensin-converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions. J Pathol. 2008; 215(3):273-279.10.1002/path.235718498093
- 38. Jacoby DS, Rader DJ. Renin-angiotensin system and atherothrombotic disease: from genes to treatment. Archives o f Internal Medicine. 2003; 163(10):1155–1164.10.1001/archinte.163.10.115512767951
- 39. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. Journal of Internal Medicine. 2008; 264(3):224–236.10.1111/j.1365-2796.2008.01981.x716693018793332
- 40. Toko H, Zou Y, Minamino T, Masaya M, Harada M, Nagai T, Sugaya T, Terasaki F, Kitaura Y, Komuro I. Angiotensin II type 1a receptor is involved in cell infiltration, cytokine production, and neovascularization in infarcted myocardium. Arterioscler Thromb Vasc Biol. 2004; 24:664–670.10.1161/01.ATV.0000122361.63827.ab14962948
- 41. Singh VP, Le B, Khode R, Baker KM, Kumar R. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes. 2008; 57(12):3297–3306.10.2337/db08-0805
- 42. Singh VP, Baker KM, Kumar R. Activation of the intracellular reninangiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production. American Journal of Physiology. 2008; 294(4):H1675–H1684.10.1152/ajpheart.91493.2007
- 43. Kumar R, Singh VP, Baker KM. The intracellular reninangiotensin system: implications in cardiovascular remodeling. Current Opinion in Nephrology and Hypertension. 2008; 17(2):168–173.10.1097/MNH.0b013e3282f521a8
- 44. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Reninangiotensin system and cardiovascular risk. The Lancet. 2007; 369(9568):1208–1219.10.1016/S0140-6736(07)60242-6
- 45. Connell JM, MacKenzie SM, Freel EM, Fraser R, Davies E. A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr Rev. 2008; 29(2):133-154.10.1210/er.2007-003018292466
- 46. Francis GS, Tang WH. Should we consider aldosterone as the primary screening target for preventing cardiovascular events? J Am Coll Cardiol. 2005; 45:1249-1250.
- 47. Stowasser M. New perspectives on the role of aldosterone excess in cardiovascular disease. Clin Exp Pharmacol Physiol. 2001; 28:783-791.10.1046/j.1440-1681.2001.03523.x11553016
- 48. Marney, A. M., and Brown, N. J. Aldosterone and end-organ damage. Clin. Sci. (Lond.) 2007; 113:267–278.
- 49. Turgeon J, McDonnell D, Martin K, Wise P. Hormone therapy: physiological complexity belies therapeutic simplicity. Science. 2004; 304(5676):1269-1273.10.1126/science.109672515166356
- 50. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007; 356(25):2591-2602.10.1056/NEJMoa07151317582069
- 51. Rossouw JE, Prentice PL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007; 297(13):1465-1477.10.1001/jama.297.13.146517405972
- 52.Herrington D.M., Reboussin D.M., Brosnihan K.B., et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis, N Engl J Med. 2000; vol. 343:522 -529.10.1056/NEJM20000824343080110954759
- 53. Manson JE, Allison MA, Rossouw JE, et al, Estrogen therapy and coronary-artery calcification. N Eng J Med. 2007; 365:2591-2602.
- 54. Tanis BC, V M, Kemmeren JM, Cats VM, Helmerhorst FM, Algra A, Van Der Graaf Y, Rosendaal FR. Oral Contraceptives and the Risk of Myocardial Infarction. N Engl J Med. 2001; 345:1787–93.10.1056/NEJMoa003216
- 55. Lidegaard O. Smoking and use of oral contraceptives: impact on thrombotic diseases. Am J Obstet Gynecol. 1999; 180:S357–63.10.1016/S0002-9378(99)70696-4
- 56. Mitchell, J.H. et al. Antioxidant efficacy of phytoestrogens in chemical and biological model systems. Arch Biochem Biophys. 1998; 360:142-148.10.1006/abbi.1998.09519826439
- 57. Kirk, E.A. et al. Dietary isoflavones reduce plasma cholesterol and atherosclerosis in C57BL/6 mice but not LDL receptor-deficient mice. J Nutr. 1998; 128, 954-959.
- 58. Anthony, M.S., Clarkson, T.B. and Williams, J.K. Effects of soy isoflavones on atherosclerosis: potential mechanisms. Am J Clin Nutr. 1998; 68, 1390S-1393S.10.1093/ajcn/68.6.1390S9848505